Abstract
In a study to determine the reliability, sensitivity, and specificity of the Chiron RIBA HIV-1/HIV-2 Strip Immunoblot Assay (RIBA HIV-1/2 SIA) for confirmation of human immunodeficiency virus type 1 (HIV-1) and HIV-2 antibodies, 1,263 serum samples from various populations in the United States, Caribbean, Africa, India, and Thailand were evaluated by RIBA HIV-1/2 SIA, and the results were compared with those obtained by an HIV-1 Western blot (immunoblot) assay. All sera were tested by HIV enzyme immunoassay, RIBA HIV-1/2 SIA, and Western blotting. Samples with discrepant results were further tested by an HIV-1 and/or HIV-2 immunofluorescent-antibody assay and HIV-1 p24 antigen assay. The RIBA HIV-1/2 SIA detected all 17 HIV-1 and HIV-2 dually reactive serum samples, all 215 HIV-2-positive serum samples, and 480 of 481 HIV-1-positive serum samples for a sensitivity of 99.8%. Of 548 negative samples, 523 were RIBA HIV-1/2 SIA negative, for a specificity of 95.4%, with 22 (4%) samples interpreted as indeterminate and 3 (0.6%) interpreted as falsely positive. Western blotting detected 391 of 548 negative samples (specificity, 71.4%), with 152 (27.7%) samples interpreted as indeterminate and 5 (0.9%) interpreted as falsely positive. In conclusion, the RIBA HIV-1/2 SIA had a sensitivity comparable to that of Western blotting and could discriminate HIV-1 from HIV-2 in one blot, providing a cost advantage. Because of its high degree of specificity, the RIBA HIV-1/2 SIA further reduced the number of indeterminate results found by Western blotting, providing a more accurate means of assessing seronegative individuals.
Full Text
The Full Text of this article is available as a PDF (152.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Busch M. P., Petersen L., Schable C., Perkins H. Monitoring blood donors for HIV-2 infection by testing anti-HIV-1 reactive sera. Transfusion. 1990 Feb;30(2):184–187. doi: 10.1046/j.1537-2995.1990.30290162908.x. [DOI] [PubMed] [Google Scholar]
- Celum C. L., Coombs R. W., Jones M., Murphy V., Fisher L., Grant C., Corey L., Inui T., Wener M. H., Holmes K. K. Risk factors for repeatedly reactive HIV-1 EIA and indeterminate western blots. A population-based case-control study. Arch Intern Med. 1994 May 23;154(10):1129–1137. [PubMed] [Google Scholar]
- Genesca J., Shih J. W., Jett B. W., Hewlett I. K., Epstein J. S., Alter H. J. What do western blot indeterminate patterns for human immunodeficiency virus mean in EIA-negative blood donors? Lancet. 1989 Oct 28;2(8670):1023–1025. doi: 10.1016/s0140-6736(89)91027-1. [DOI] [PubMed] [Google Scholar]
- Guyader M., Emerman M., Sonigo P., Clavel F., Montagnier L., Alizon M. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 1987 Apr 16;326(6114):662–669. doi: 10.1038/326662a0. [DOI] [PubMed] [Google Scholar]
- Horsburgh C. R., Jr, Holmberg S. D. The global distribution of human immunodeficiency virus type 2 (HIV-2) infection. Transfusion. 1988 Mar-Apr;28(2):192–195. doi: 10.1046/j.1537-2995.1988.28288179031.x. [DOI] [PubMed] [Google Scholar]
- Jackson J. B., MacDonald K. L., Cadwell J., Sullivan C., Kline W. E., Hanson M., Sannerud K. J., Stramer S. L., Fildes N. J., Kwok S. Y. Absence of HIV infection in blood donors with indeterminate western blot tests for antibody to HIV-1. N Engl J Med. 1990 Jan 25;322(4):217–222. doi: 10.1056/NEJM199001253220402. [DOI] [PubMed] [Google Scholar]
- Kanki P. J., Barin F., M'Boup S., Allan J. S., Romet-Lemonne J. L., Marlink R., McLane M. F., Lee T. H., Arbeille B., Denis F. New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM). Science. 1986 Apr 11;232(4747):238–243. doi: 10.1126/science.3006256. [DOI] [PubMed] [Google Scholar]
- Knüver-Hopf J., Heinze H., Lambrecht B., Mohr H., Beyer J., Schmitt H. Blood donations indeterminate in HIV-1 western blot analysed by IgM immunoblot and polymerase chain reaction. Vox Sang. 1993;64(2):89–93. doi: 10.1111/j.1423-0410.1993.tb02524.x. [DOI] [PubMed] [Google Scholar]
- MacDonald K. L., Jackson J. B., Bowman R. J., Polesky H. F., Rhame F. S., Balfour H. H., Jr, Osterholm M. T. Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications. Ann Intern Med. 1989 Apr 15;110(8):617–621. doi: 10.7326/0003-4819-110-8-617. [DOI] [PubMed] [Google Scholar]
- Midthun K., Garrison L., Clements M. L., Farzadegan H., Fernie B., Quinn T. Frequency of indeterminate western blot tests in healthy adults at low risk for human immunodeficiency virus infection. The NIAID AIDS Vaccine Clinical Trails Network. J Infect Dis. 1990 Dec;162(6):1379–1382. doi: 10.1093/infdis/162.6.1379. [DOI] [PubMed] [Google Scholar]
- Phair J., Hoover D., Huprikar J., Detels R., Kaslow R., Rinaldo C., Saah A. The significance of western blot assays indeterminate for antibody to HIV in a cohort of homosexual/bisexual men. The Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1992 Oct;5(10):988–992. [PubMed] [Google Scholar]
- Schwartz J. S., Dans P. E., Kinosian B. P. Human immunodeficiency virus test evaluation, performance, and use. Proposals to make good tests better. JAMA. 1988 May 6;259(17):2574–2579. [PubMed] [Google Scholar]
- Westblom T. U., Belshe R. B., Gorse G. J., Anderson E. L., Berry C. F. Characteristics of a population volunteering for human immunodeficiency virus immunization. NIAID AIDS Clinical Trials Network. Int J STD AIDS. 1990 Mar;1(2):126–128. doi: 10.1177/095646249000100211. [DOI] [PubMed] [Google Scholar]